Validation of Selected Head and Neck Cancer Prognostic Markers from the Pathology Atlas in an Oral Tongue Cancer Cohort
Authors:
- Anna Maria WirsingAWAnna Maria Wirsing
- Inger-Heidi BjerkliIBInger-Heidi Bjerkli
- Sonja Eriksson SteigenSSSonja Eriksson Steigen
- Oddveig RikardsenOROddveig Rikardsen
- Synnøve Norvoll MagnussenSMSynnøve Norvoll Magnussen
- Beate HeggeBHBeate Hegge
- Marit SeppolaMSMarit Seppola
- Lars Uhlin-HansenLULars Uhlin-Hansen
- Elin Hadler-OlsenEHElin Hadler-Olsen
Open Access
Abstract
The Pathology Atlas is an open-access database that reports the prognostic value of protein-coding transcripts in 17 cancers, including head and neck cancer. However, cancers of the various head and neck anatomical sites are specific biological entities. Thus, the aim of the present study was to validate promising prognostic markers for head and neck cancer reported in the Pathology Atlas in oral tongue squamous cell carcinoma (OTSCC). We selected three promising markers from the Pathology Atlas (CALML5, CD59, LIMA1), and analyzed their prognostic value in a Norwegian OTSCC cohort comprising 121 patients. We correlated target protein and mRNA expression in formalin-fixed, paraffin-embedded cancer tissue to five-year disease-specific survival (DSS) in univariate and multivariate analyses. Protein expression of CALML5 and LIMA1 were significantly associated with five-year DSS in the OTSCC cohort in univariate analyses (p = 0.016 and p = 0.043, respectively). In multivariate analyses, lymph node metastases, tumor differentiation, and CALML5 were independent prognosticators. The prognostic role of the other selected markers for head and neck cancer patients identified through unbiased approaches could not be validated in our OTSCC cohort. This underlines the need for subsite-specific analyses for head and neck cancer.Keywords
Funding Information
- The North Norwegian Regional Health Authorities (SFP1276-16)
This publication has 32 references indexed in Scilit:
- Specific expression of k63-linked ubiquitination of calmodulin-like protein 5 in breast cancer of premenopausal patientsJournal of Cancer Research and Clinical Oncology, 2013
- Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaborationBMC Medicine, 2012
- EPLIN downregulation promotes epithelial–mesenchymal transition in prostate cancer cells and correlates with clinical lymph node metastasisOncogene, 2011
- Lifestyle risk factors for oral cancerOral Oncology, 2009
- Eplin-alpha expression in human breast cancer, the impact on cellular migration and clinical outcomeMolecular Cancer, 2008
- Identification and transcript analysis of a novel wallaby (Macropus eugenii) basal-like breast cancer cell lineMolecular Cancer, 2008
- Membrane complement regulatory proteinsClinical Immunology, 2006
- REporting recommendations for tumour MARKer prognostic studies (REMARK)European Journal of Cancer, 2005
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001
- EPLIN, Epithelial protein lost in neoplasmOncogene, 1999